Ask - Cardio tablets p / o 100mg, No. 30

• unstable angina;

• stable angina pectoris;

• primary prevention of acute myocardial infarction in the presence of risk factors (for example, diabetes mellitus, hyperlipidemia, arterial hypertension, obesity, smoking, old age) and repeated myocardial infarction;

• prevention of ischemic stroke (including in patients with transient cerebrovascular accident);

• prevention of transient disorders of cerebral circulation;

• prevention of thromboembolism after surgery and invasive interventions on the vessels (for example, coronary artery bypass grafting, endarterectomy of the carotid arteries, arteriovenous bypass grafting, angioplasty of the carotid arteries);

• prevention of deep vein thrombosis and thromboembolism of the pulmonary arteries and its branches (for example, with prolonged immobilization as a result of major surgery).

ASA-cardioЃ should be taken orally, preferably before meals, without chewing, with plenty of water.

ASK-cardioЃ is intended for long-term use.

The duration of therapy is determined by the attending physician. In the absence of other prescriptions, the following dosing regimen is recommended:
Unstable angina (if acute myocardial infarction is suspected), an initial dose of 100-300 mg (the first tablet must be chewed for faster absorption) should be taken by the patient as soon as possible, after the suspicion arose on the development of acute myocardial infarction. In the next 30 days after the development of myocardial infarction, a dose of 200-300 mg per day should be maintained.

Primary prevention of acute myocardial infarction in the presence of risk factors 100 mg per day or 300 mg every other day.

Prevention of recurrent myocardial infarction. Unstable and stable angina. Prevention of ischemic stroke and transient cerebrovascular accident. Prevention of thromboembolism after operations and invasive interventions on vessels 100-300 mg per day.

Prevention of deep vein thrombosis and thromboembolism of the pulmonary artery and its branches 100-200 mg per day or 300 mg every other day.

active substance: acetylsalicylic acid 100 mg;
excipients:
core: lactose monohydrate (milk sugar) 15.87 mg; povidone (polyvinyl pyrrolidone) 0.16 mg; potato starch 3.57 mg; talc 0.2 mg; stearic acid 0.2 mg
shell: methacrylic acid and ethacrylate copolymer [1: 1] (colicoate MAE 100) 4.186 mg; macrogol-6000 (high molecular weight polyethylene glycol) 0.558 mg; talc 1.117 mg; titanium dioxide 0.139 mg.

• hypersensitivity to acetylsalicylic acid (ASA), to excipients of the drug and other non-steroidal anti-inflammatory drugs (NSAIDs);

• erosive and ulcerative lesions of the gastrointestinal tract in the acute stage; gastrointestinal bleeding;

• bronchial asthma induced by the intake of salicylates and NSAIDs; complete or incomplete combination of bronchial asthma, recurrent polyposis of the nose and paranasal sinuses and intolerance to ASA or other NSAIDs, including a history;

• hemorrhagic diathesis (hemophilia, von Willebrand disease, telangiectasia, hypoproteinemia, thrombocytopenia, thrombocytopenic purpura);

• combined use with methotrexate at a dose of 15 mg per week or more;

• pregnancy (I and III trimester) and the period of breastfeeding;

• age under 18;

• severe renal failure (creatinine clearance (CC) less than 30 ml /

• severe hepatic impairment (class B and higher according to the Chald-Pugh classification);

• chronic heart failure III-IV functional class according to NYHA classification;

• lactose intolerance, lactase deficiency and glucose-galactose malabsorption.

Carefullyprescribed to patients with gout, hyperuricemia; in the presence of a history of ulcerative lesions of the gastrointestinal tract or gastrointestinal bleeding; renal failure (CC more than 30 ml / min); liver failure (below class B according to the Chald-Pugh classification); bronchial asthma, chronic respiratory diseases, hay fever, nasal polyposis, drug allergies, including the group of NSAIDs (analgesics, anti-inflammatory, antirheumatic drugs); in the second trimester of pregnancy; vitamin K deficiency; with severe forms of glucose-6-phosphate dehydrogenase deficiency; with a proposed surgical intervention (including minor, for example, tooth extraction); with simultaneous use with the following drugs (with methotrexate at a dose of less than 15 mg per week, with anticoagulants,thrombolytic or antiplatelet agents; with NSAIDs, ibuprofen, salicylic acid derivatives in high doses, with digoxin; with hypoglycemic agents for oral administration (sulfonylurea derivatives) and insulin, with valproic acid, with alcohol, with selective serotonin reuptake inhibitors), with uricosuric drugs, ACE inhibitors, diuretics, glucocorticosteroids.

Trade name:

ASK-cardioЃ

International non-proprietary or group name:

acetylsalicylic acid

Dosage form:

enteric tablets, film-coated.

Composition for 1 tablet:

active substance: acetylsalicylic acid 100 mg;
excipients:
core: lactose monohydrate (milk sugar) 15.87 mg; povidone (polyvinyl pyrrolidone) 0.16 mg; potato starch 3.57 mg; talc 0.2 mg; stearic acid 0.2 mg
shell: methacrylic acid and ethacrylate copolymer [1: 1] (colicoate MAE 100) 4.186 mg; macrogol-6000 (high molecular weight polyethylene glycol) 0.558 mg; talc 1.117 mg; titanium dioxide 0.139 mg.

Description:

round biconvex white film-coated tablets. In the cross section, the core is white.

Pharmacotherapeutic group:

antiplatelet agent.

ATX code:

B01AC06

Pharmacological properties

Pharmacodynamics
Acetylsalicylic acid (ASA) is an ester of salicylic acid, belongs to the group of non-steroidal anti-inflammatory drugs (NSAIDs). The mechanism of action is based on the irreversible inactivation of the enzyme cyclooxygenase (COX-1), as a result of which the synthesis of prostaglandins, prostacyclins and thromboxane is blocked. Reduces aggregation, platelet adhesion and thrombus formation by suppressing the synthesis of thromboxane A2 in platelets. Increases the fibrinolytic activity of blood plasma and reduces the concentration of vitamin K-dependent coagulation factors (II, VII, IX, X). The antiplatelet effect develops after the use of small doses of the drug and lasts for 7 days after a single dose. These properties of ASA are used in the prevention and treatment of myocardial infarction, coronary heart disease, complications of varicose veins.ASA in high doses (more than 300 mg) has anti-inflammatory, antipyretic and analgesic effects.

Pharmacokinetics
After oral administration, ASA is rapidly and completely absorbed from the gastrointestinal tract (GIT). ASA is partially metabolized during absorption. During and after absorption, ASA is converted into the main metabolite - salicylic acid, which is metabolized mainly in the liver under the influence of enzymes with the formation of such metabolites as phenyl salicylate, glucuronide salicylate and salicyluric acid, found in many tissues and in urine. In women, the metabolic process is slower (less enzyme activity in the blood serum). The maximum concentration of ASA in blood plasma is achieved within 10-20 minutes after ingestion, salicylic acid - in 0.3-2 hours. Due to the fact that the tablets are coated with an acid-resistant coating, ASA is not released in the stomach (the membrane effectively blocks the dissolution of the drug in the stomach),and in the alkaline environment of the duodenum. Thus, the absorption of ASA in the dosage form of enteric film-coated tablets is slowed down by 3-6 hours in comparison with conventional (without such a coating) tablets.
ASA and salicylic acid bind strongly to blood plasma proteins (from 66% to 98% depending on the dose) and are rapidly distributed in the body. Salicylic acid crosses the placenta and is secreted in breast milk.
The excretion of salicylic acid is dose-dependent, since its metabolism is limited by the capabilities of the enzymatic system. The half-life is from 2-3 hours when using ASA in low doses and up to 15 hours when using the drug in high doses (usual doses of acetylsalicylic acid as an analgesic). Unlike other salicylates, with repeated administration of the drug, non-hydrolyzed ASA does not accumulate in the blood serum. Salicylic acid and its metabolites are excreted by the kidneys. In patients with normal renal function, 80-100% of a single dose of the drug is excreted by the kidneys within 24-72 hours.

Indications for use

• unstable angina;

• stable angina pectoris;

• primary prevention of acute myocardial infarction in the presence of risk factors (for example, diabetes mellitus, hyperlipidemia, arterial hypertension, obesity, smoking, old age) and repeated myocardial infarction;

• prevention of ischemic stroke (including in patients with transient cerebrovascular accident);

• prevention of transient disorders of cerebral circulation;

• prevention of thromboembolism after surgery and invasive interventions on the vessels (for example, coronary artery bypass grafting, endarterectomy of the carotid arteries, arteriovenous bypass grafting, angioplasty of the carotid arteries);

• prevention of deep vein thrombosis and thromboembolism of the pulmonary arteries and its branches (for example, with prolonged immobilization as a result of major surgery).

Contraindications for use

• hypersensitivity to acetylsalicylic acid (ASA), to excipients of the drug and other non-steroidal anti-inflammatory drugs (NSAIDs);

• erosive and ulcerative lesions of the gastrointestinal tract in the acute stage; gastrointestinal bleeding;

• bronchial asthma induced by the intake of salicylates and NSAIDs; complete or incomplete combination of bronchial asthma, recurrent polyposis of the nose and paranasal sinuses and intolerance to ASA or other NSAIDs, including a history;

• hemorrhagic diathesis (hemophilia, von Willebrand disease, telangiectasia, hypoproteinemia, thrombocytopenia, thrombocytopenic purpura);

• combined use with methotrexate at a dose of 15 mg per week or more;

• pregnancy (I and III trimester) and the period of breastfeeding;

• age under 18;

• severe renal failure (creatinine clearance (CC) less than 30 ml /

• severe hepatic impairment (class B and higher according to the Chald-Pugh classification);

• chronic heart failure III-IV functional class according to NYHA classification;

• lactose intolerance, lactase deficiency and glucose-galactose malabsorption.

Carefullyprescribed to patients with gout, hyperuricemia; in the presence of a history of ulcerative lesions of the gastrointestinal tract or gastrointestinal bleeding; renal failure (CC more than 30 ml / min); liver failure (below class B according to the Chald-Pugh classification); bronchial asthma, chronic respiratory diseases, hay fever, nasal polyposis, drug allergies, including the group of NSAIDs (analgesics, anti-inflammatory, antirheumatic drugs); in the second trimester of pregnancy; vitamin K deficiency; with severe forms of glucose-6-phosphate dehydrogenase deficiency; with a proposed surgical intervention (including minor, for example, tooth extraction); with simultaneous use with the following drugs (with methotrexate at a dose of less than 15 mg per week, with anticoagulants,thrombolytic or antiplatelet agents; with NSAIDs, ibuprofen, salicylic acid derivatives in high doses, with digoxin; with hypoglycemic agents for oral administration (sulfonylurea derivatives) and insulin, with valproic acid, with alcohol, with selective serotonin reuptake inhibitors), with uricosuric drugs, ACE inhibitors, diuretics, glucocorticosteroids.

Application during pregnancy and during breastfeeding

The use of the drug is contraindicated during pregnancy (I and III trimesters) and during breastfeeding. The use of large doses of salicylates in the first 3 months of pregnancy is associated with an increased incidence of fetal defects (cleft palate, heart defects). In the second trimester of pregnancy, salicylates can be prescribed only with a rigorous assessment of the risks and benefits.
In the last trimester of pregnancy, salicylates in a high dose (more than 300 mg / day) cause a weakening of labor, premature closure of the ductus arteriosus in the fetus, increased bleeding in the mother and fetus, and administration just before childbirth can cause intracranial hemorrhage, especially in premature babies. The appointment of salicylates in the last trimester is contraindicated.
Salicylates and their metabolites pass into breast milk in small amounts. Accidental intake of salicylates during breastfeeding is not accompanied by the development of adverse reactions in the child and does not require termination of breastfeeding. However, with long-term use of the drug or the appointment of a high dose, breastfeeding should be stopped immediately.

Dosage regimen, route of administration

ASA-cardioЃ should be taken orally, preferably before meals, without chewing, with plenty of water.

ASK-cardioЃ is intended for long-term use.

The duration of therapy is determined by the attending physician. In the absence of other prescriptions, the following dosing regimen is recommended:
Unstable angina (if acute myocardial infarction is suspected), an initial dose of 100-300 mg (the first tablet must be chewed for faster absorption) should be taken by the patient as soon as possible, after the suspicion arose on the development of acute myocardial infarction. In the next 30 days after the development of myocardial infarction, a dose of 200-300 mg per day should be maintained.

Primary prevention of acute myocardial infarction in the presence of risk factors 100 mg per day or 300 mg every other day.

Prevention of recurrent myocardial infarction. Unstable and stable angina. Prevention of ischemic stroke and transient cerebrovascular accident. Prevention of thromboembolism after operations and invasive interventions on vessels 100-300 mg per day.

Prevention of deep vein thrombosis and thromboembolism of the pulmonary artery and its branches 100-200 mg per day or 300 mg every other day.

Side effect

Disturbances from the gastrointestinal tract: the most common are nausea, heartburn, vomiting, pain in the abdomen; rarely - stomach and duodenal ulcers, including perforated, gastrointestinal bleeding; transient liver dysfunctions with increased activity of 'hepatic' transaminases.
Heart disorders: In rare cases, increased symptoms of chronic heart failure.
Vascular disorders: in rare cases - edema of the lower extremities.
Blood and lymphatic system disorders:increased frequency of perioperative (intra- and postoperative) bleeding, hematomas, nosebleeds, bleeding gums, bleeding from the urinary tract. There are reports of serious cases of bleeding, which include gastrointestinal and cerebral hemorrhages (especially in hypertensive patients who have not reached blood pressure (BP) targets and / or received concomitant anticoagulant therapy), which in some cases may be life-threatening. Bleeding can lead to the development of acute or chronic post-hemorrhagic / iron-deficiency anemia (for example, due to latent bleeding) with corresponding clinical and laboratory symptoms (asthenia, pallor, hypoperfusion).There are reports of cases of hemolysis and hemolytic anemia in patients with severe glucose-6-phosphate dehydrogenase deficiency.
Disorders of the urinary system: there are reports of cases of development of impaired renal function and acute renal failure. Nervous system disorders: dizziness, hearing loss, tinnitus, which may be a sign of drug overdose (see Overdose section).
Immune system disorders: hypersensitivity reactions with corresponding laboratory and clinical manifestations such as asthmatic syndrome (bronchospasm), mild to moderate reactions of the skin, respiratory tract, gastrointestinal tract and cardiovascular system, including symptoms such as skin rash, pruritus , urticaria, Quincke's edema, rhinitis, edema of the nasal mucosa, cardio-respiratory distress syndrome, as well as severe reactions, including anaphylactic shock.

Overdose

May have serious consequences, especially in the elderly and in children. Salicylism syndrome develops when ASA is taken at a dose of more than 100 mg / kg / day for more than 2 days due to the use of toxic doses of the drug in the framework of improper therapeutic use (chronic poisoning) or a single accidental or deliberate intake of a toxic dose of the drug by an adult or a child (acute poisoning) ...
Overdose symptoms:
- For mild to moderate severity (single dose less than 150 mg / kg): Dizziness, tinnitus, hearing loss, increased sweating, nausea and vomiting, headache, confusion, tachypnea, hyperventilation, respiratory alkalosis.
Treatment:gastric lavage, repeated intake of activated carbon, forced alkaline diuresis, restoration of water-electrolyte balance and acid-base state.
- With moderate and severe severity (single dose 150 mg / kg-300 mg / kg - moderate severity, more than 300 mg / kg - severe poisoning):
Respiratory alkalosis with compensatory metabolic acidosis, hyperpyrexia, hyperventilation, noncardiogenic pulmonary edema, respiratory depression, asphyxia; on the part of the cardiovascular system: heart rhythm disturbances, pronounced decrease in blood pressure, inhibition of cardiac activity; on the part of the water-electrolyte balance: dehydration, impaired renal function from oliguria up to the development of renal failure, characterized by hypokalemia, hypernatremia, hyponatremia; violation of glucose metabolism: hyperglycemia, hypoglycemia (especially in children), ketoacidosis; tinnitus, deafness; gastrointestinal bleeding; hematological disorders: from inhibition of platelet aggregation to coagulopathy, prolongation of prothrombin time, hypoprothrombinemia; neurological disorders:toxic encephalopathy and depression of the function of the central nervous system (drowsiness, confusion, coma, convulsions).
Treatment: immediate hospitalization in specialized departments for emergency therapy - gastric lavage, repeated intake of activated charcoal, forced alkaline diuresis, hemodialysis, restoration of water-electrolyte balance and acid-base state, symptomatic therapy.

Interaction with other medicinal products

With the simultaneous use of ASA enhances the effect of the following drugs; if necessary, the simultaneous use of ASA with the listed agents should consider the need to reduce the dose of drugs:
- methotrexate, by reducing renal clearance and displacing it from the connection with proteins;
- with simultaneous use with anticoagulants, thrombolytic and antiplatelet agents (ticlopidine, clopidogrel), there is an increase in the risk of bleeding as a result of the synergism of the main therapeutic effects of the drugs used;
- with simultaneous use with drugs with anticoagulant, thrombolytic or antiplatelet effect, there is an increase in the damaging effect on the mucous membrane of the gastrointestinal tract;
- selective serotonin reuptake inhibitors, which can lead to an increased risk of bleeding from the upper gastrointestinal tract (synergism with ASA);
- digoxin, due to a decrease in its renal excretion, which can lead to an overdose;
- hypoglycemic agents for oral administration (sulfonylurea derivatives) and insulin due to the hypoglycemic properties of ASA itself in high doses and displacement of sulfonylurea derivatives from the connection with blood plasma proteins;
- with simultaneous use with valproic acid, its toxicity increases due to the displacement of its connection with blood plasma proteins;
- NSAIDs and salicylic acid derivatives in high doses (increased risk of ulcerogenic effect and bleeding from the gastrointestinal tract as a result of synergistic action); with simultaneous use with ibuprofen, antagonism is observed with respect to irreversible inhibition of platelets due to the action of ASA, which leads to a decrease in the cardioprotective effects of ASA;
- Ethanol (increased risk of damage to the mucous membrane of the gastrointestinal tract and lengthening of bleeding time as a result of the mutual enhancement of the effects of ASA and ethanol);
- With the simultaneous use of acetylsalicylic acid (as an antiplatelet agent) and blockers of 'slow' calcium channels, the risk of bleeding increases;
- When used simultaneously with gold preparations, acetylsalicylic acid can induce liver damage.

With the simultaneous use of ASA in high doses, it weakens the effect of the drugs listed below; if it is necessary to simultaneously prescribe ASA with the listed drugs, consider the need to adjust the dose of the listed drugs:
- any diuretics (when combined with ASA in high doses, there is a decrease in the glomerular filtration rate (GFR) as a result of a decrease in the synthesis of prostaglandins in the kidneys);
- ингибиторы ангиотензинпревращающего фермента (јѕ‘) (отмечаетс¤ дозозависимое снижение — ‘ в результате ингибировани¤ простагландинов, обладающих сосудорасшир¤ющим действием, соответственно, ослабление гипотензивного действи¤.  линическое снижение — ‘ отмечаетс¤ при суточной дозе ј—  более 160 мг.  роме того, отмечаетс¤ снижение положительного кардиопротективного действи¤ ингибиторов јѕ‘, назначенных пациентам дл¤ терапии хронической сердечной недостаточности. Ётот эффект также про¤вл¤етс¤ при применении совместно с ј—  в больших дозах);
- препараты с урикозурическим действием Ц бензбромарон, пробенецид (снижение урикозурического эффекта вследствие конкурентного подавлени¤ почечной канальцевой экскреции мочевой кислоты);
- при одновременном применении с системными глюкокортикостероидами (за исключением гидрокортизона, используемого дл¤ заместительной терапии болезни јддисона) отмечаетс¤ усиление выведени¤ салицилатов и соответственно ослабление их действи¤.
јнтациды, содержащие магний и/или алюминий, замедл¤ют и ухудшают всасывание ацетилсалициловой кислоты.

ќсобые указани¤

ѕрепарат следует примен¤ть после назначени¤ врача.
ј—  может провоцировать бронхоспазм, а также вызывать приступы бронхиальной астмы и другие реакции повышенной чувствительности. ‘акторами риска ¤вл¤ютс¤ наличие бронхиальной астмы в анамнезе, сенной лихорадки, полипоза носа, хронических заболеваний дыхательной системы, а также аллергических реакций на другие препараты (например, кожные реакции, зуд, крапивница).
ј—  может вызвать кровотечени¤ различной степени выраженности во врем¤ и после хирургических вмешательств, поэтому при необходимости абсолютного исключени¤ кровоточивости в ходе оперативного вмешательства необходимо, по возможности, полностью отказатьс¤ от применени¤ ј—  в предоперационном периоде.
—очетание ј—  с антикоагул¤нтами, тромболитиками и антиагрегантными препаратами сопровождаетс¤ повышенным риском развити¤ кровотечений.
ј—  в низких дозах может спровоцировать развитие подагры у предрасположенных лиц (имеющих сниженную экскрецию мочевой кислоты).
—очетание ј—  с метотрексатом сопровождаетс¤ повышенной частотой развити¤ побочных эффектов со стороны органов кроветворени¤.
¬ысокие дозы ј—  оказывают гипогликемический эффект, что необходимо иметь в виду при назначении ее пациентам с сахарным диабетом, получающим гипогликемические препараты дл¤ приема внутрь и инсулин.
ѕри сочетании глюкокортикостероидов (v —) и салицилатов следует помнить, что во врем¤ лечени¤ уровень салицилатов в крови снижен, а после отмены v — возможна передозировка салицилатов.
Ќе рекомендуетс¤ сочетание ј—  с ибупрофеном у пациентов с повышенным риском сердечно Ц сосудистых заболеваний, поскольку последний снижает положительное вли¤ние ј—  на продолжительность жизни (снижает кардиопротективный эффект ј— ).
ѕревышение дозы ј—  сопр¤жено с риском желудочно-кишечного кровотечени¤.
ѕередозировка особенно опасна у пациентов пожилого возраста.
ѕри сочетании ј—  с алкоголем повышен риск повреждени¤ слизистой оболочки желудочно-кишечного тракта и удлинение времени кровотечени¤.
¬ период лечени¤ необходимо соблюдать осторожность при выполнении потенциально опасных видов де¤тельности, требующих повышенной концентрации внимани¤ и быстроты психомоторных реакций (вождение автотранспорта, работа с движущимис¤ механизмами, работа диспетчера и оператора и т.п.), так как возможно развитие головокружени¤.
ј—  с осторожностью назначают пациентам с подагрой, гиперурикемией; при наличии в анамнезе ¤звенных поражений желудочно-кишечного тракта или желудочно-кишечных кровотечений; почечной недостаточности (   более 30 мл/мин); печеночной недостаточности (ниже класса ¬ по классификации „алд-ѕью); бронхиальной астмы, хронических заболеваний органов дыхани¤, сенной лихорадки, полипоза носа, лекарственной аллергии, в том числе группы Ќѕ¬ѕ (анальгетики, противовоспалительные, противоревматические средства); во II триместре беременности; дефиците витамина  ; при т¤жЄлых формах дефицита глюкозо-6-фосфатдегидрогеназы; при предполагаемом хирургическом вмешательстве (включа¤ незначительные, например, экстракци¤ зуба); при одновременном применении со следующими лекарственными средствами (с метотрексатом в дозе менее 15 мг в неделю, с антикоагул¤нтными, тромболитическими или антиагрегантными средствами; с Ќѕ¬ѕ, ибупрофеном, производными салициловой кислоты в больших дозах, с дигоксином; с гипогликемическими средствами дл¤ приЄма внутрь (производные сульфонилмочевины) и инсулином, с вальпроевой кислотой, с алкоголем, с селективными ингибиторами обратного захвата серотонина), с урикозурическими препаратами, ингибиторами јѕ‘, диуретиками, глюкокортикостероидами.

¬ли¤ние на способность управл¤ть транспортными средствами, механизмами

¬ период лечени¤ необходимо соблюдать осторожность при выполнении потенциально опасных видов де¤тельности, требующих повышенной концентрации внимани¤ и быстроты психомоторных реакций (вождение автотранспорта, работа с движущимис¤ механизмами, работа диспетчера и оператора и т.п.), так как возможно развитие головокружени¤.

‘орма выпуска

“аблетки кишечнорастворимые, покрытые пленочной оболочкой, 100 мг.
ѕо 10 таблеток в контурную ¤чейковую упаковку из пленки поливинилхлоридной и фольги алюминиевой печатной лакированной.
ѕо 30, 50, 60 или 100 таблеток в банки полимерные.
 аждую банку или 1, 2, 3, 5, 6, 10 контурных ¤чейковых упаковок с инструкцией по применению помещают в пачку из картона.

—рок годности

4 years.
Do not use the drug after the expiration date indicated on the package.

Storage conditions

In a dry place at a temperature not exceeding 25 ? C.
Keep out of the reach of children.

Vacation conditions

Available without a prescription.

Manufacturer / Organization accepting claims:

JSC 'Medisorb', Russia
Legal address: 614113, Perm, st. Galperina, 6
Address of the place of production: 614113, Perm, st. Prichalnaya, 1b